To validate the efficacy of the DNA vaccine for different MHC haplotypes and tumor types, we used subcutaneous LLC/3LL tumors in CB57/BL6 mice, which have a different MHC class 1 haplotype, H-2b. This evidence concerns the gene HLA-C and neoplasm.